MedTrace Logo

Control of Myopia Using Novel Spectacle Lens Designs

NCT03623074 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 266

Last updated 2026-05-05

No results posted yet for this study

Summary

Randomized, controlled, multisite, subject-and observer-masked, 3-arm parallel group clinical trial of 36-month duration to evaluate the safety and efficacy of a novel spectacle lens design in reducing the progression of juvenile myopia.

Conditions

  • Juvenile Myopia

Interventions

DEVICE

Novel spectacle lens design

Use of lenses may reduce the rate of progression of juvenile myopia

DEVICE

Spectacle lenses

Use of lenses may reduce the rate of progression of juvenile myopia

Sponsors & Collaborators

  • SightGlass Vision, Inc.

    lead INDUSTRY

Principal Investigators

  • Joseph Rappon, OD, MS, FAAO · SightGlass Vision, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
10 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-16
Primary Completion
2022-05-15
Completion
2026-12-31
FDA Device
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03623074 on ClinicalTrials.gov